NR565 Advanced Pharmacology Fundamentals Midterm Exam Chamberlain University 2026-2027
NR565 / NR 565 Advanced Pharmacology Fundamentals
Midterm Examination
Latest Update | Graded A+ | 100% Guarantee | Verified by Experts
Chamberlain University College of Nursing
75 Questions | Multiple Choice (A-D) | One Correct Answer Per Question
Section 1: Foundational Pharmacology Principles and Pharmacokinetics (Q1-Q15)
Q1: A 45-year-old patient is prescribed a medication with high first-pass metabolism. The nurse practitioner
understands that which of the following best describes the first-pass effect?
A. The drug is metabolized by CYP3A4 in the intestinal wall before systemic absorption
B. The drug undergoes extensive hepatic metabolism before reaching systemic circulation, reducing
bioavailability [CORRECT]
C. The drug is rapidly excreted by the kidneys before it can reach its target tissue
D. The drug binds extensively to plasma proteins, limiting its free concentration at the site of action
Correct Answer: B
Rationale: The first-pass effect refers to pre-systemic metabolism primarily in the liver after oral absorption but before the
drug reaches systemic circulation. Drugs with significant first-pass metabolism (e.g., propranolol, morphine, lidocaine) have
substantially reduced oral bioavailability, often necessitating higher oral doses or alternative routes. Option A describes only
intestinal metabolism, which is one component but not the complete definition. Option C describes renal excretion, a separate
elimination process. Option D describes protein binding affecting distribution, not first-pass metabolism.
Q2: A nurse is administering an intravenous medication and explains to the patient that the bioavailability of
this drug is 100%. Which of the following is the best rationale for this?
A. IV administration bypasses hepatic first-pass metabolism, delivering the full dose directly into systemic
circulation [CORRECT]
B. IV drugs have a larger volume of distribution compared to oral medications
C. IV medications are not bound to plasma proteins, increasing the free drug concentration
D. IV administration results in faster renal clearance, ensuring complete drug delivery to tissues
Correct Answer: A
Rationale: Intravenous administration provides 100% bioavailability (F = 1.0) because the drug is delivered directly into
systemic circulation, completely bypassing gastrointestinal absorption and hepatic first-pass metabolism. Option B describes
volume of distribution, a separate pharmacokinetic parameter. Option C is incorrect because IV drugs can still be
protein-bound. Option D confuses bioavailability with renal clearance, an unrelated elimination parameter.
Q3: A 65-year-old patient with hypoalbuminemia is started on a highly protein-bound drug (99% bound to
albumin). The nurse practitioner anticipates which of the following effects?
A. Decreased volume of distribution and reduced therapeutic effect
B. Increased free drug concentration with higher risk of toxicity [CORRECT]
C. Enhanced first-pass metabolism due to reduced protein binding
D. Increased renal clearance because of reduced protein binding in the blood
Correct Answer: B
Rationale: Highly protein-bound drugs rely on albumin for transport. In hypoalbuminemia, fewer binding sites are available,
leading to increased free (unbound) pharmacologically active drug fraction, raising both therapeutic efficacy and toxicity
risk. Option A is incorrect because reduced protein binding typically increases the volume of distribution for the free fraction.
Option C is incorrect because protein binding does not directly affect first-pass metabolism. Option D is incorrect because
Page 1
,NR565 Advanced Pharmacology Fundamentals Midterm Exam Chamberlain University 2026-2027
reduced protein binding does not inherently increase renal clearance.
Q4: A patient taking phenytoin for seizure management is prescribed erythromycin for a respiratory infection.
The nurse practitioner should anticipate which of the following drug interactions?
A. Decreased phenytoin levels due to CYP450 induction by erythromycin
B. Increased phenytoin levels due to CYP3A4 inhibition by erythromycin, risk of toxicity [CORRECT]
C. No significant interaction because phenytoin is primarily renally eliminated
D. Enhanced protein binding of phenytoin, reducing its free concentration
Correct Answer: B
Rationale: Erythromycin is a macrolide antibiotic and a moderate CYP3A4 inhibitor. Phenytoin is primarily metabolized by
CYP2C9 and CYP2C19, but erythromycin also inhibits these isoenzymes, reducing phenytoin metabolism and increasing
serum concentrations, elevating toxicity risk including nystagmus, ataxia, and gingival hyperplasia. Option A is incorrect
because erythromycin is an inhibitor, not an inducer. Option C is incorrect because phenytoin is primarily hepatically
metabolized. Option D incorrectly describes the interaction mechanism.
Q5: A patient with chronic liver disease is prescribed a medication that undergoes Phase II metabolism
(conjugation). Compared to a healthy individual, this patient will most likely experience which of the
following?
A. Enhanced drug metabolism due to upregulation of conjugating enzymes
B. No change in drug metabolism because Phase II reactions are not affected by liver disease
C. Prolonged half-life and potential drug accumulation due to impaired conjugation capacity [CORRECT]
D. Rapid drug elimination through increased renal compensatory mechanisms
Correct Answer: C
Rationale: Phase II metabolism (conjugation: glucuronidation, sulfation, acetylation) occurs primarily in the liver. Chronic
liver disease impairs both Phase I and Phase II reactions, leading to decreased drug clearance, prolonged half-life, and
potential drug accumulation. Option A is incorrect because liver disease downregulates metabolic enzymes. Option B is
incorrect because both phases are affected by hepatic impairment. Option D is incorrect because renal compensation cannot
fully compensate for impaired hepatic metabolism.
Q6: A nurse practitioner is educating a patient about a new medication with a narrow therapeutic index.
Which of the following statements by the patient indicates an accurate understanding?
A. I can adjust my dose based on how I feel each day without checking with my provider
B. I need to have regular blood tests to make sure the drug level is safe and effective [CORRECT]
C. This medication is very safe because only a small amount is needed for effect
D. I should take this medication with food to increase its absorption and effectiveness
Correct Answer: B
Rationale: A narrow therapeutic index means the difference between effective and toxic doses is small. Drugs like digoxin
(0.5-0.9 ng/mL), lithium (0.6-1.2 mEq/L), and warfarin require regular therapeutic drug monitoring to ensure serum
concentrations remain within the therapeutic window. Option A is dangerous. Option C incorrectly equates narrow TI with
safety. Option D is unrelated to therapeutic index.
Q7: A patient is taking a drug that undergoes enterohepatic recirculation. The nurse understands that this
process will have which effect on the drug?
A. Prolonged half-life and extended duration of action due to repeated reabsorption from the GI tract
[CORRECT]
B. Shortened half-life because the drug is rapidly eliminated through bile
C. Increased first-pass metabolism reducing the overall bioavailability
D. Decreased protein binding because the drug is sequestered in the bile
Correct Answer: A
Rationale: Enterohepatic recirculation occurs when a drug is conjugated in the liver, excreted into bile, released into the
intestine, deconjugated by intestinal bacteria, and reabsorbed. This significantly extends the drug half-life and duration of
action. Examples include estrogen, doxycycline, and certain beta-lactam antibiotics. Options B, C, and D describe unrelated
Page 2
, NR565 Advanced Pharmacology Fundamentals Midterm Exam Chamberlain University 2026-2027
pharmacokinetic processes.
Q8: A 70-year-old patient is prescribed a water-soluble drug. Compared to a lipid-soluble drug, the
water-soluble drug will most likely have which pharmacokinetic profile?
A. High volume of distribution with extensive tissue penetration
B. Limited distribution primarily confined to extracellular fluid and plasma [CORRECT]
C. Enhanced ability to cross the blood-brain barrier
D. Prolonged half-life due to extensive tissue storage
Correct Answer: B
Rationale: Water-soluble drugs have limited ability to cross lipid membranes, are primarily confined to extracellular fluid
and plasma, and have a relatively small volume of distribution. Lipid-soluble drugs readily cross cell membranes, distribute
widely into tissues including the CNS, and have larger volumes of distribution. Options A, C, and D all describe characteristics
of lipid-soluble drugs.
Q9: A patient is prescribed rifampin for tuberculosis treatment. The nurse practitioner knows that rifampin
will affect concurrent medications through which mechanism?
A. CYP450 enzyme inhibition leading to increased drug levels of co-administered medications
B. CYP450 enzyme induction leading to decreased drug levels of co-administered medications [CORRECT]
C. Increased protein binding of other drugs, reducing their free concentrations
D. Inhibition of renal tubular secretion, increasing drug levels of renally eliminated medications
Correct Answer: B
Rationale: Rifampin is one of the most potent CYP450 inducers, particularly of CYP3A4 and CYP2C9. Enzyme induction
increases metabolic enzyme synthesis, accelerating metabolism of co-administered CYP450 substrates, decreasing serum
concentrations, and potentially causing therapeutic failure. Other strong inducers include phenytoin, carbamazepine, and St.
John's Wort. Option A describes the opposite effect. Options C and D describe unrelated mechanisms.
Q10: A drug has a half-life of 12 hours. Approximately how long will it take to reach steady-state
concentration with repeated dosing?
A. 12 hours (one half-life)
B. 24 hours (two half-lives)
C. 60 hours (five half-lives) [CORRECT]
D. 120 hours (ten half-lives)
Correct Answer: C
Rationale: Steady-state concentration is achieved when the rate of drug administration equals the rate of elimination. It takes
approximately 4-5 half-lives to reach 94-97% of steady-state. For a drug with a 12-hour half-life, steady-state is reached in
approximately 60 hours (5 x 12 = 60 hours). One half-life reaches 50%, two half-lives reach 75%, and ten half-lives is
unnecessarily prolonged.
Q11: A patient with renal impairment is prescribed a medication primarily eliminated through glomerular
filtration. The nurse practitioner should expect which pharmacokinetic change?
A. Decreased half-life and increased clearance of the drug
B. Increased half-life and potential accumulation leading to toxicity [CORRECT]
C. No significant change because tubular secretion compensates for reduced filtration
D. Increased volume of distribution due to fluid retention
Correct Answer: B
Rationale: Renal impairment reduces GFR, decreasing clearance of drugs eliminated by filtration. This leads to prolonged
half-life and potential drug accumulation with repeated dosing, necessitating dose adjustment for renally-cleared drugs such
as aminoglycosides, digoxin, and certain antibiotics. Option A describes the opposite effect. Option C is incorrect because
tubular secretion is also impaired. Option D confuses distribution with elimination impairment.
Q12: A nursing student asks about the blood-brain barrier (BBB) and drug penetration. Which statement by
the nurse practitioner is most accurate?
Page 3
NR565 / NR 565 Advanced Pharmacology Fundamentals
Midterm Examination
Latest Update | Graded A+ | 100% Guarantee | Verified by Experts
Chamberlain University College of Nursing
75 Questions | Multiple Choice (A-D) | One Correct Answer Per Question
Section 1: Foundational Pharmacology Principles and Pharmacokinetics (Q1-Q15)
Q1: A 45-year-old patient is prescribed a medication with high first-pass metabolism. The nurse practitioner
understands that which of the following best describes the first-pass effect?
A. The drug is metabolized by CYP3A4 in the intestinal wall before systemic absorption
B. The drug undergoes extensive hepatic metabolism before reaching systemic circulation, reducing
bioavailability [CORRECT]
C. The drug is rapidly excreted by the kidneys before it can reach its target tissue
D. The drug binds extensively to plasma proteins, limiting its free concentration at the site of action
Correct Answer: B
Rationale: The first-pass effect refers to pre-systemic metabolism primarily in the liver after oral absorption but before the
drug reaches systemic circulation. Drugs with significant first-pass metabolism (e.g., propranolol, morphine, lidocaine) have
substantially reduced oral bioavailability, often necessitating higher oral doses or alternative routes. Option A describes only
intestinal metabolism, which is one component but not the complete definition. Option C describes renal excretion, a separate
elimination process. Option D describes protein binding affecting distribution, not first-pass metabolism.
Q2: A nurse is administering an intravenous medication and explains to the patient that the bioavailability of
this drug is 100%. Which of the following is the best rationale for this?
A. IV administration bypasses hepatic first-pass metabolism, delivering the full dose directly into systemic
circulation [CORRECT]
B. IV drugs have a larger volume of distribution compared to oral medications
C. IV medications are not bound to plasma proteins, increasing the free drug concentration
D. IV administration results in faster renal clearance, ensuring complete drug delivery to tissues
Correct Answer: A
Rationale: Intravenous administration provides 100% bioavailability (F = 1.0) because the drug is delivered directly into
systemic circulation, completely bypassing gastrointestinal absorption and hepatic first-pass metabolism. Option B describes
volume of distribution, a separate pharmacokinetic parameter. Option C is incorrect because IV drugs can still be
protein-bound. Option D confuses bioavailability with renal clearance, an unrelated elimination parameter.
Q3: A 65-year-old patient with hypoalbuminemia is started on a highly protein-bound drug (99% bound to
albumin). The nurse practitioner anticipates which of the following effects?
A. Decreased volume of distribution and reduced therapeutic effect
B. Increased free drug concentration with higher risk of toxicity [CORRECT]
C. Enhanced first-pass metabolism due to reduced protein binding
D. Increased renal clearance because of reduced protein binding in the blood
Correct Answer: B
Rationale: Highly protein-bound drugs rely on albumin for transport. In hypoalbuminemia, fewer binding sites are available,
leading to increased free (unbound) pharmacologically active drug fraction, raising both therapeutic efficacy and toxicity
risk. Option A is incorrect because reduced protein binding typically increases the volume of distribution for the free fraction.
Option C is incorrect because protein binding does not directly affect first-pass metabolism. Option D is incorrect because
Page 1
,NR565 Advanced Pharmacology Fundamentals Midterm Exam Chamberlain University 2026-2027
reduced protein binding does not inherently increase renal clearance.
Q4: A patient taking phenytoin for seizure management is prescribed erythromycin for a respiratory infection.
The nurse practitioner should anticipate which of the following drug interactions?
A. Decreased phenytoin levels due to CYP450 induction by erythromycin
B. Increased phenytoin levels due to CYP3A4 inhibition by erythromycin, risk of toxicity [CORRECT]
C. No significant interaction because phenytoin is primarily renally eliminated
D. Enhanced protein binding of phenytoin, reducing its free concentration
Correct Answer: B
Rationale: Erythromycin is a macrolide antibiotic and a moderate CYP3A4 inhibitor. Phenytoin is primarily metabolized by
CYP2C9 and CYP2C19, but erythromycin also inhibits these isoenzymes, reducing phenytoin metabolism and increasing
serum concentrations, elevating toxicity risk including nystagmus, ataxia, and gingival hyperplasia. Option A is incorrect
because erythromycin is an inhibitor, not an inducer. Option C is incorrect because phenytoin is primarily hepatically
metabolized. Option D incorrectly describes the interaction mechanism.
Q5: A patient with chronic liver disease is prescribed a medication that undergoes Phase II metabolism
(conjugation). Compared to a healthy individual, this patient will most likely experience which of the
following?
A. Enhanced drug metabolism due to upregulation of conjugating enzymes
B. No change in drug metabolism because Phase II reactions are not affected by liver disease
C. Prolonged half-life and potential drug accumulation due to impaired conjugation capacity [CORRECT]
D. Rapid drug elimination through increased renal compensatory mechanisms
Correct Answer: C
Rationale: Phase II metabolism (conjugation: glucuronidation, sulfation, acetylation) occurs primarily in the liver. Chronic
liver disease impairs both Phase I and Phase II reactions, leading to decreased drug clearance, prolonged half-life, and
potential drug accumulation. Option A is incorrect because liver disease downregulates metabolic enzymes. Option B is
incorrect because both phases are affected by hepatic impairment. Option D is incorrect because renal compensation cannot
fully compensate for impaired hepatic metabolism.
Q6: A nurse practitioner is educating a patient about a new medication with a narrow therapeutic index.
Which of the following statements by the patient indicates an accurate understanding?
A. I can adjust my dose based on how I feel each day without checking with my provider
B. I need to have regular blood tests to make sure the drug level is safe and effective [CORRECT]
C. This medication is very safe because only a small amount is needed for effect
D. I should take this medication with food to increase its absorption and effectiveness
Correct Answer: B
Rationale: A narrow therapeutic index means the difference between effective and toxic doses is small. Drugs like digoxin
(0.5-0.9 ng/mL), lithium (0.6-1.2 mEq/L), and warfarin require regular therapeutic drug monitoring to ensure serum
concentrations remain within the therapeutic window. Option A is dangerous. Option C incorrectly equates narrow TI with
safety. Option D is unrelated to therapeutic index.
Q7: A patient is taking a drug that undergoes enterohepatic recirculation. The nurse understands that this
process will have which effect on the drug?
A. Prolonged half-life and extended duration of action due to repeated reabsorption from the GI tract
[CORRECT]
B. Shortened half-life because the drug is rapidly eliminated through bile
C. Increased first-pass metabolism reducing the overall bioavailability
D. Decreased protein binding because the drug is sequestered in the bile
Correct Answer: A
Rationale: Enterohepatic recirculation occurs when a drug is conjugated in the liver, excreted into bile, released into the
intestine, deconjugated by intestinal bacteria, and reabsorbed. This significantly extends the drug half-life and duration of
action. Examples include estrogen, doxycycline, and certain beta-lactam antibiotics. Options B, C, and D describe unrelated
Page 2
, NR565 Advanced Pharmacology Fundamentals Midterm Exam Chamberlain University 2026-2027
pharmacokinetic processes.
Q8: A 70-year-old patient is prescribed a water-soluble drug. Compared to a lipid-soluble drug, the
water-soluble drug will most likely have which pharmacokinetic profile?
A. High volume of distribution with extensive tissue penetration
B. Limited distribution primarily confined to extracellular fluid and plasma [CORRECT]
C. Enhanced ability to cross the blood-brain barrier
D. Prolonged half-life due to extensive tissue storage
Correct Answer: B
Rationale: Water-soluble drugs have limited ability to cross lipid membranes, are primarily confined to extracellular fluid
and plasma, and have a relatively small volume of distribution. Lipid-soluble drugs readily cross cell membranes, distribute
widely into tissues including the CNS, and have larger volumes of distribution. Options A, C, and D all describe characteristics
of lipid-soluble drugs.
Q9: A patient is prescribed rifampin for tuberculosis treatment. The nurse practitioner knows that rifampin
will affect concurrent medications through which mechanism?
A. CYP450 enzyme inhibition leading to increased drug levels of co-administered medications
B. CYP450 enzyme induction leading to decreased drug levels of co-administered medications [CORRECT]
C. Increased protein binding of other drugs, reducing their free concentrations
D. Inhibition of renal tubular secretion, increasing drug levels of renally eliminated medications
Correct Answer: B
Rationale: Rifampin is one of the most potent CYP450 inducers, particularly of CYP3A4 and CYP2C9. Enzyme induction
increases metabolic enzyme synthesis, accelerating metabolism of co-administered CYP450 substrates, decreasing serum
concentrations, and potentially causing therapeutic failure. Other strong inducers include phenytoin, carbamazepine, and St.
John's Wort. Option A describes the opposite effect. Options C and D describe unrelated mechanisms.
Q10: A drug has a half-life of 12 hours. Approximately how long will it take to reach steady-state
concentration with repeated dosing?
A. 12 hours (one half-life)
B. 24 hours (two half-lives)
C. 60 hours (five half-lives) [CORRECT]
D. 120 hours (ten half-lives)
Correct Answer: C
Rationale: Steady-state concentration is achieved when the rate of drug administration equals the rate of elimination. It takes
approximately 4-5 half-lives to reach 94-97% of steady-state. For a drug with a 12-hour half-life, steady-state is reached in
approximately 60 hours (5 x 12 = 60 hours). One half-life reaches 50%, two half-lives reach 75%, and ten half-lives is
unnecessarily prolonged.
Q11: A patient with renal impairment is prescribed a medication primarily eliminated through glomerular
filtration. The nurse practitioner should expect which pharmacokinetic change?
A. Decreased half-life and increased clearance of the drug
B. Increased half-life and potential accumulation leading to toxicity [CORRECT]
C. No significant change because tubular secretion compensates for reduced filtration
D. Increased volume of distribution due to fluid retention
Correct Answer: B
Rationale: Renal impairment reduces GFR, decreasing clearance of drugs eliminated by filtration. This leads to prolonged
half-life and potential drug accumulation with repeated dosing, necessitating dose adjustment for renally-cleared drugs such
as aminoglycosides, digoxin, and certain antibiotics. Option A describes the opposite effect. Option C is incorrect because
tubular secretion is also impaired. Option D confuses distribution with elimination impairment.
Q12: A nursing student asks about the blood-brain barrier (BBB) and drug penetration. Which statement by
the nurse practitioner is most accurate?
Page 3
